Establishment Labs (ESTA) Competitors

$71.87 +0.10 (+0.14%)

As of 03:51 PM Eastern

ESTA vs. GKOS, BLCO, STVN, NVST, and IRTC

Should you be buying Establishment Labs stock or one of its competitors? The main competitors of Establishment Labs include Glaukos (GKOS), Bausch + Lomb (BLCO), Stevanato Group (STVN), Envista (NVST), and iRhythm Technologies (IRTC). These companies are all part of the "medical equipment" industry.

How does Establishment Labs compare to Glaukos?

Glaukos (NYSE:GKOS) and Establishment Labs (NASDAQ:ESTA) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

Establishment Labs has lower revenue, but higher earnings than Glaukos. Establishment Labs is trading at a lower price-to-earnings ratio than Glaukos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	15.62	-$187.69M	-$3.28	N/A
Establishment Labs	$211.08M	10.01	-$51.06M	-$1.49	N/A

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 72.9% of Establishment Labs shares are owned by institutional investors. 6.4% of Glaukos shares are owned by company insiders. Comparatively, 10.0% of Establishment Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Glaukos currently has a consensus target price of $144.42, indicating a potential upside of 6.98%. Establishment Labs has a consensus target price of $87.14, indicating a potential upside of 21.26%. Given Establishment Labs' higher possible upside, analysts clearly believe Establishment Labs is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Establishment Labs had 7 more articles in the media than Glaukos. MarketBeat recorded 20 mentions for Establishment Labs and 13 mentions for Glaukos. Glaukos' average media sentiment score of 0.51 beat Establishment Labs' score of 0.27 indicating that Glaukos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Establishment Labs	8 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Establishment Labs has a net margin of -19.05% compared to Glaukos' net margin of -34.34%. Glaukos' return on equity of -6.92% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-34.34%	-6.92%	-5.25%
Establishment Labs	-19.05%	-202.78%	-12.39%

Glaukos has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Establishment Labs has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.

Summary

Glaukos beats Establishment Labs on 10 of the 17 factors compared between the two stocks.

How does Establishment Labs compare to Bausch + Lomb?

Establishment Labs (NASDAQ:ESTA) and Bausch + Lomb (NYSE:BLCO) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Establishment Labs presently has a consensus target price of $87.14, indicating a potential upside of 21.26%. Bausch + Lomb has a consensus target price of $18.08, indicating a potential upside of 12.70%. Given Establishment Labs' stronger consensus rating and higher probable upside, research analysts clearly believe Establishment Labs is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

In the previous week, Establishment Labs had 8 more articles in the media than Bausch + Lomb. MarketBeat recorded 20 mentions for Establishment Labs and 12 mentions for Bausch + Lomb. Bausch + Lomb's average media sentiment score of 1.20 beat Establishment Labs' score of 0.27 indicating that Bausch + Lomb is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	8 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bausch + Lomb	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

72.9% of Establishment Labs shares are held by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are held by institutional investors. 10.0% of Establishment Labs shares are held by insiders. Comparatively, 1.5% of Bausch + Lomb shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Bausch + Lomb has a net margin of -4.21% compared to Establishment Labs' net margin of -19.05%. Bausch + Lomb's return on equity of 3.60% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-19.05%	-202.78%	-12.39%
Bausch + Lomb	-4.21%	3.60%	1.69%

Establishment Labs has higher earnings, but lower revenue than Bausch + Lomb. Establishment Labs is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	10.01	-$51.06M	-$1.49	N/A
Bausch + Lomb	$5.10B	1.12	-$360M	-$0.62	N/A

Establishment Labs has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500.

Summary

Establishment Labs beats Bausch + Lomb on 9 of the 16 factors compared between the two stocks.

How does Establishment Labs compare to Stevanato Group?

Establishment Labs (NASDAQ:ESTA) and Stevanato Group (NYSE:STVN) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

In the previous week, Establishment Labs had 8 more articles in the media than Stevanato Group. MarketBeat recorded 20 mentions for Establishment Labs and 12 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 0.27 beat Establishment Labs' score of 0.27 indicating that Stevanato Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	8 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Stevanato Group	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Establishment Labs presently has a consensus target price of $87.14, indicating a potential upside of 21.26%. Given Establishment Labs' stronger consensus rating and higher probable upside, equities analysts clearly believe Establishment Labs is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Stevanato Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Stevanato Group has a net margin of 11.76% compared to Establishment Labs' net margin of -19.05%. Stevanato Group's return on equity of 10.27% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-19.05%	-202.78%	-12.39%
Stevanato Group	11.76%	10.27%	6.08%

Stevanato Group has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	10.01	-$51.06M	-$1.49	N/A
Stevanato Group	€1.34B	4.13	€158.21M	€0.59	30.98

72.9% of Establishment Labs shares are owned by institutional investors. 10.0% of Establishment Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Establishment Labs has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.

Summary

Establishment Labs and Stevanato Group tied by winning 8 of the 16 factors compared between the two stocks.

How does Establishment Labs compare to Envista?

Envista (NYSE:NVST) and Establishment Labs (NASDAQ:ESTA) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

Envista has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, Establishment Labs has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.

In the previous week, Envista had 3 more articles in the media than Establishment Labs. MarketBeat recorded 23 mentions for Envista and 20 mentions for Establishment Labs. Envista's average media sentiment score of 0.61 beat Establishment Labs' score of 0.27 indicating that Envista is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Envista	4 Very Positive mention(s)	5 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Establishment Labs	8 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Envista has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envista	$2.81B	1.40	$47M	$0.41	58.74
Establishment Labs	$211.08M	10.01	-$51.06M	-$1.49	N/A

Envista currently has a consensus target price of $28.83, suggesting a potential upside of 19.72%. Establishment Labs has a consensus target price of $87.14, suggesting a potential upside of 21.26%. Given Establishment Labs' stronger consensus rating and higher possible upside, analysts clearly believe Establishment Labs is more favorable than Envista.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envista	0 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Envista has a net margin of 2.41% compared to Establishment Labs' net margin of -19.05%. Envista's return on equity of 7.11% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Envista	2.41%	7.11%	3.91%
Establishment Labs	-19.05%	-202.78%	-12.39%

72.9% of Establishment Labs shares are held by institutional investors. 1.0% of Envista shares are held by company insiders. Comparatively, 10.0% of Establishment Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Envista beats Establishment Labs on 9 of the 15 factors compared between the two stocks.

How does Establishment Labs compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and Establishment Labs (NASDAQ:ESTA) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

iRhythm Technologies has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, Establishment Labs has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.

In the previous week, Establishment Labs had 16 more articles in the media than iRhythm Technologies. MarketBeat recorded 20 mentions for Establishment Labs and 4 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.07 beat Establishment Labs' score of 0.27 indicating that iRhythm Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRhythm Technologies	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Establishment Labs	8 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

72.9% of Establishment Labs shares are held by institutional investors. 1.0% of iRhythm Technologies shares are held by company insiders. Comparatively, 10.0% of Establishment Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

iRhythm Technologies has higher revenue and earnings than Establishment Labs. iRhythm Technologies is trading at a lower price-to-earnings ratio than Establishment Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$787.85M	4.89	-$44.55M	-$0.86	N/A
Establishment Labs	$211.08M	10.01	-$51.06M	-$1.49	N/A

iRhythm Technologies has a net margin of -3.53% compared to Establishment Labs' net margin of -19.05%. iRhythm Technologies' return on equity of -10.26% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-3.53%	-10.26%	-1.39%
Establishment Labs	-19.05%	-202.78%	-12.39%

iRhythm Technologies currently has a consensus target price of $193.38, suggesting a potential upside of 64.98%. Establishment Labs has a consensus target price of $87.14, suggesting a potential upside of 21.26%. Given iRhythm Technologies' stronger consensus rating and higher possible upside, research analysts clearly believe iRhythm Technologies is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

iRhythm Technologies beats Establishment Labs on 12 of the 17 factors compared between the two stocks.

Get Establishment Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ESTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ESTA vs. The Competition

Export

Metric	Establishment Labs	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.11B	$8.18B	$6.18B	$12.28B
Dividend Yield	N/A	2.86%	2.78%	5.22%
P/E Ratio	-48.18	22.52	20.71	25.72
Price / Sales	10.01	16.63	527.52	65.20
Price / Cash	N/A	12.66	27.81	36.27
Price / Book	88.72	4.92	9.80	6.76
Net Income	-$51.06M	$183.43M	$3.54B	$333.20M
7 Day Performance	N/A	N/A	N/A	0.52%
1 Month Performance	19.40%	7.59%	6.48%	9.27%
1 Year Performance	111.31%	1.35%	42.26%	42.97%

Establishment Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ESTA Establishment Labs	2.9022 of 5 stars	$71.87 +0.1%	$87.14 +21.3%	+111.0%	$2.11B	$211.08M	N/A	1,004	Earnings Report Insider Trade
GKOS Glaukos	2.0211 of 5 stars	$133.49 -1.7%	$138.85 +4.0%	+48.1%	$7.81B	$507.44M	N/A	1,094
BLCO Bausch + Lomb	4.1343 of 5 stars	$16.04 -1.6%	$18.08 +12.8%	+44.1%	$5.70B	$5.10B	N/A	13,000
STVN Stevanato Group	3.581 of 5 stars	€17.96 +1.4%	N/A	-23.8%	€5.41B	€1.34B	30.80	6,010	Earnings Report
NVST Envista	2.4058 of 5 stars	$25.85 +0.2%	$28.25 +9.3%	+37.7%	$4.20B	$2.72B	92.14	12,000	Earnings Report Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ESTA) was last updated on 5/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Establishment Labs (ESTA) Competitors

ESTA vs. GKOS, BLCO, STVN, NVST, and IRTC

How does Establishment Labs compare to Glaukos?

Summary

How does Establishment Labs compare to Bausch + Lomb?

Summary

How does Establishment Labs compare to Stevanato Group?

Summary

How does Establishment Labs compare to Envista?

Summary

How does Establishment Labs compare to iRhythm Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESTA vs. The Competition

Establishment Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Establishment Labs (ESTA) Competitors

ESTA vs. GKOS, BLCO, STVN, NVST, and IRTC

How does Establishment Labs compare to Glaukos?

Which has stronger earnings and valuation, GKOS or ESTA?

Do insiders & institutionals believe in GKOS or ESTA?

Do analysts rate GKOS or ESTA?

Does the media favor GKOS or ESTA?

Is GKOS or ESTA more profitable?

Which has more risk & volatility, GKOS or ESTA?

Summary

How does Establishment Labs compare to Bausch + Lomb?

Do analysts prefer ESTA or BLCO?

Does the media prefer ESTA or BLCO?

Do institutionals & insiders have more ownership in ESTA or BLCO?

Is ESTA or BLCO more profitable?

Which has preferable valuation and earnings, ESTA or BLCO?

Which has more risk & volatility, ESTA or BLCO?

Summary

How does Establishment Labs compare to Stevanato Group?

Does the media prefer ESTA or STVN?

Do analysts prefer ESTA or STVN?

Is ESTA or STVN more profitable?

Which has better valuation & earnings, ESTA or STVN?

Do insiders and institutionals have more ownership in ESTA or STVN?

Which has more volatility and risk, ESTA or STVN?

Summary

How does Establishment Labs compare to Envista?

Which has more risk & volatility, NVST or ESTA?

Does the media favor NVST or ESTA?

Which has stronger earnings and valuation, NVST or ESTA?

Do analysts recommend NVST or ESTA?

Is NVST or ESTA more profitable?

Do institutionals and insiders have more ownership in NVST or ESTA?

Summary

How does Establishment Labs compare to iRhythm Technologies?

Which has more risk & volatility, IRTC or ESTA?

Does the media favor IRTC or ESTA?

Do institutionals and insiders have more ownership in IRTC or ESTA?

Which has stronger earnings and valuation, IRTC or ESTA?

Is IRTC or ESTA more profitable?

Do analysts recommend IRTC or ESTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESTA vs. The Competition

Establishment Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools